Retrospective Cohort Study of Effectiveness and Safety of Adalimumab Use in Children with Juvenile Idiopathic Arthritis in the Republic of Bashkortostan

Background: Methotrexate is the first-line drug for treating patients with juvenile idiopathic arthritis (JIA). If it is ineffective or intolerable, prescription of genetically engineered biopharmaceuticals is indicated. Objective: The study was aimed at assessing effectiveness and safety of genetically engineered biopharmaceutical adalimumab for treating children with JIA. Methods: A retrospective cohort study was conducted to analyze results of treating patients with JIA aged 2–17 years. Adalimumab would be prescribed biweekly in the dose of 24 mg/m2 (body surface) subcutaneously (if body weight is under 30 kg) or in the dose of 40 mg/m2 (if body weight is > 30 kg). Effectiveness and safety would be assessed after 4–12–24–48–96 weeks. Results: We analyzed treatment results of 17 patients (15 children with active joint syndrome, 2 — with active uveitis). All patients with active joint syndrome had been receiving adalimumab for 12 weeks, 12 patients — for 24 weeks, 8 — for 48 weeks, 5 — for 96 weeks. 30/50/70% improvement in terms of the ACRpedi criteria was observed in 15/11/4 children after 4 weeks, after 12 weeks — in 15/13/11 patients, after 48 weeks — in 7/6/6 patients. The status of inactive disease was established in 5 patients (33%) after 12 weeks, after 24 weeks — in 9 children (75%), after 48 weeks — in 7 children (70%), after 96 weeks — in 4 (80%) children. Active uveitis was terminated in all 5 patients with signs of eye damage in the treatment onset. 1 patient suffered from exacerbation of the disease after 48 weeks of therapy; the drug was withdrawn. Tubercular infection without local manifestations was established in 1 patient after 96 weeks (positive Mantoux test, papule — 10 mm). Adalimumab injection was terminated for the period of chemotherapy. Conclusion: Adalimumab has a sufficiently high effectiveness and safety for long-term (up to 2 years) treatment of children with JIA. 

1. Cassidy J, Petty R, Laxer RM, Lindsley CB. Textbook of Pediatric Rheumatology. 6th ed. Elsevier. 2011. 794 p.

2. Малиевский ВА. Ювенильные артриты: эпидемиология, медико-социальные и экономические последствия, качество жизни. Автореф. дис. ... докт. мед. наук. М. 2006. 38 с.

3. Ruth NM, Passo MH. Juvenile idiopathic arthritis: management and therapeutic options. Ther Adv Musculoskel Dis. 2012; 4(2):99–110.

4. Баранов АА, Алексеева ЕИ, Бзарова ТМ, Валиева СИ, Денисова РВ, Исаева КБ, Карагулян НА, Литвицкий ПФ, Митенко ЕВ, Слепцова ТВ, Фетисова АН, Чистякова ЕГ, Тайбулатов НИ, Морев СЮ. Протокол ведения пациентов с ювенильным артритом. Вопросы современной педиатрии. 2013;12(1):2–16.

5. Ruth N, Passo M. Juvenile idiopathic arthritis: management and therapeutic options. Ther Adv Musculoskel Dis. 2012;4(2):99–110.

6. Lowell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008:359:810–820.

7. Lovell D, Ruperto N, Kingsbury DJ, Burgos-Vargas R, Imagawa T, Horneff G, Quartier P, Goodman S, Reiff A, Giannini EH, Cardoso A, Anderson JK, Varothai NA, Kalabic J, Martini A. Long-Term Safety of Adalimumab Treatment in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis and Enthesitis-Related Arthritis [abstract]. Arthritis Rheum.2015;67 (Suppl 10). URL: http://acrabstracts.org/ abstract/long-term-safety-of-adalimumab-treatment-in-pediatricpatients-with-polyarticular-juvenile-idiopathic-arthritis-andenthesitis-related-arthritis/(Available: 21.11.2015).

8. Ruperto N, Lovell DL, Reiff A, Gamir M, Higgins G, Kone-Paut I, Jones OY, Chalom E, Ilowite N, Wouters C, McIlraith MG, Liu S, Kupper H, Giannini TH, Martini A. Long-term efficacy and safety of adalimumab in 4–12 year old patients with juvenile idiopathic arthritis. Pediatric Rheumatology. 2011;9(Suppl 1):26.

9. Kingsbury D, Quartier P, Arora V, Kalabic J, Kupper H, Mozaffarian N. Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to < 4 years or 4 years weighing < 15 kg. Ann Rheum Dis. 2013;72(Suppl 3):729. 10. Алексеева ЕИ, Митенко ЕВ, Валиева СИ, Бзарова ТМ, Денисова РВ, Исаева КБ, Слепцова ТВ, Чомахидзе АМ. Эффективность и безопасность терапии адалимумабом у детей с ювенильным идиопатическим артритом и увеитом. Вопросы современной педиатрии. 2012;11(1):69–74.

10. Алексеева ЕИ, Баранов АА, Митенко ЕВ, Бзарова ТМ, Валиева СИ, Денисова РВ, Исаева КБ, Чистякова ЕГ, Слепцова ТВ, Тайбулатов НИ, Зеликович ЕИ, Куриленков ГВ. Эффективность и безопасность полностью идентичных человеческих моноклональных антител к ФНО у детей с ювенильным идиопатическим артритом при первичной и вторичной неэффективности других биологических препаратов. Вестник РАМН. 2013;11:73–82.

11. Schmeling H, Horneff G. Efficacy and Safety of Adalimumab in children with juvenile idiopathic arthritis. Ann Rheum Dis. 2013; 72(Suppl 3):71.

12. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 2004;31:390–392.

13. Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2290–2294.

14. Consolaro A, Ruperto N, Bazso F, Pistorio A, Magni-Manzoni S, Filocamo G, Malattia C., Viola S, Martini A, Ravelli A. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Care & Res. 2009;61(5):658–666.

15. Кузьмина НН, Никишина ИП, Шайков АВ, Руперта Н, Шелепина ТА, Салугина СО. Российский адаптированный вариант опросников для оценки качества жизни и состояния здоровья детей с ювенильными хроническими артритами. Научно-практическая ревматология. 2002;1:40–47.

16. Consolaro A, Negro G, Lanni S, Solari N, Martini A, Ravelli A. Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. Clin. Exp. Rheimatol. 2012;30(4)157–162.

17. Beukelman T, Berntson L, Duffy CM, Guzman G, Kimura Y, Klotsche J. The initial treatment of systemic juvenile idiopathic arthritis: an international collaboration among 7 registries. Ann Rheum Dis. 2015;1613.

18. Pohjankoski H, Latva K, Kautiainen H, Saila H, Klaukka T, Virta L, Puolakka K, Pohjolainen T, Savolainen A. First-year purchases disease-modifying drugs of incident patients with chronic juvenile arthritis in Finland. Clin Exp Rheum. 2011;29(5):878–881.

19. Beukelman T, Ringold S, Davis TE, DeWitt E, Pelajo CF, Weiss PF, Kimura Y. DMARD use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the childhood arthritis and rheumatology research alliance (CARRA) Registry. Ann Rheum Dis. 2012;71(Suppl 3):438.

20. Minden K, Klotsche J, Niewerth M, Zink A, Seipel E, Haas JP, Ganser G, Horneff G. How tolerable is methotrexate in the longterm use in juvenile idiopathic arthritis (JIA)? Ann Rheum Dis. 2015;74(Suppl.2):609.

21. Klotsche О, Minden K, Niewerth M et al. Is early treatment with biologics associated with a better long-term outcome in patients with polyarticular Juvenile idiopathic arthritis (JIA)? Ann Rheum Dis. 2013;72(Suppl 3):739.

22. Romano M, Pontikaki I, Gattinara M, Salmaso A, Teruzzi B, Donati C et al. Clinical remission and drug survival in 301 juvenile idiopathic arthritis patients treated with biological therapies. Ann Rheum Dis. 2011;70(Suppl 3):407.

23. Scardapane A, Ferrante R, Nozzi M, Marzetti V, Lucantoni M, Marsili M, Stuppia L, Chiarelli F, Breda L. TNF-alpha gene polymorphisms and juvenile idiopathic arthritis: influence on disease outcome and therapeutic response. Ann Rheum Dis. 2015;74(Suppl 2):611.

24. Horneff G, Huppertz H, Haas P, Tenbrock K, Minden K. Drug survival and reasons for discontinuation of biological therapy in 1679 polyarticular juvenile idiopathic arthritis patients. Ann Rheum Dis. 2015;74(Suppl 2):92.

25. Camacho-Lovillo M, Gil-Gonzalez E, Gantes Pedraza MA, Lopez-Sabido MA. Discontinuation of anti-TNF in patients with juvenile idiopathic arthritis in clinical remission. Ann Rheum Dis. 2015;74(Suppl 2):388.